Synchron also reported evidence the device worked in the six-patient trial, with the conversion of brain signals to motor ...

Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease ...

Researchers assessed the safety, efficacy, and tolerability of various doses of zasocitinib among patients with moderate to severe plaque psoriasis.

Overall, 255,789 patients made 953,402 primary care visits during UC and 228,255 patients made 615,511 visits during SC.

Bispecific antibodies (bsAbs) are engineered to target 2 different epitopes simultaneously. About 75% of the 16 clinically ...